FLOT and CROSS chemotherapy regimens alter the frequency of CD27⁺ and CD69⁺ T cells in oesophagogastric adenocarcinomas: implications for combination with immunotherapy.

ABSTRACT: Combining immunostimulatory chemotherapies with immunotherapy is an attractive strategy to enhance treatment responses in oesophagogastric junctional adenocarcinoma (OGJ). This study investigates the immunostimulatory properties of FLOT, CROSS and MAGIC chemotherapy regimens in the context of OGJ using in vitro and ex vivo models of the treatment-naïve and post-chemotherapy treated tumour microenvironment. FLOT and CROSS chemotherapy regimens increased surrogate markers of immunogenic cell death (HMGB1 and HLA-DR), whereas the MAGIC treatment regimen decreased HMGB1 and HLA-DR on OGJ cells (markedly for epirubicin). Tumour-infiltrating and circulating T cells had significantly lower CD27 expression and significantly higher CD69 expression post-FLOT and post-CROSS treatment. Similarly, the

SUBMITTER: Davern M 

PROVIDER: S-EPMC10314858 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature